Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Humedics Starts LiMAx Phase III Trial on Liver Function Analysis for Severe Liver Surgery

Published: Monday, March 04, 2013
Last Updated: Monday, March 04, 2013
Bookmark and Share
First patients being included directly after study initiation in Berlin and Jena.

Humedics GmbH has announced the start of a clinical phase III trial. The main goal of this study is the early identification of low-risk patients after partial liver resection by the LiMAx test and improvements in patient management based on test results.

After the initiation of first study centers in January, first patients already have been enrolled in Berlin and Jena.

The trial with the short title 'Fast-track LiveR' is a prospective, randomized, controlled, multi-centric, phase III study for the early identification of low-risk patients after partial liver resection with the LiMAx test.

A major goal is to demonstrate the benefit for the patient and the impact on clinical thinking related to a different postoperative management (fast-track procedure) with immediate transfer of patients with good liver function from the recovery room to general ward.

Erwin de Buijzer, Managing Director of Humedics GmbH, commented the trial start: “The start of our phase III study is a milestone on the way to the approval of our LiMAx test and thus for the further company development of Humedics. We want to provide physicians with a new diagnostic procedure to enable a reliable liver function analysis prior and after liver surgery, to adapt therapy options respectively and thereby contributing to optimized and cost efficient healthcare. After we received the official approval for conducting the study from the German Federal Institute for Drugs and Medical Devices (BundesinstitutfürArzneimittel und Medizinprodukte, BfArM) and the positive vote of the ethics committee end of 2012 we were able to start immediately with the initiation of the first study centers early this year. We are very excited that Berlin and Jena already have enrolled the first patients within such a short time span.”

Chief Investigator PD Dr. Martin Stockmann from Charité - Universitätsmedizin Berlin at the Campus Virchow Hospital, Dept. of General, Visceral and Graft Surgery, added “Liver surgery with a partial removal of the liver implies a general risk of postoperative complications including severe complications like liver failure. So far, an analysis of the remaining liver function was not possible. The LiMAx test of Humedics has the potential to address this medical need and thus to optimize and individualize patient management. In the clinical practice this may result, for example, in decision-making on the basis of liver function analysis if a patient needs to be further treated in an Intensive Care Unit or if he can be transferred to general ward.”

Prof. Dr. UtzSettmacher, Director of the Dept. of General and Visceral Surgery and responsible for the Fast-track LiveR study center at the Jena University Hospital, said: “With the LiMAx test we are able to directly determine the liver function and thus to assess much better the outcome of liver surgery. This is new and both - clinician and patient - benefit from the test. We are very pleased to take part in this important trial and also about the fact that we have been able to include patients within the first days after study initiation.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Humedics Co-founder Martin Stockmann Awarded with Von-Langenbeck Prize
Award ceremony at the annual conference of the German Society of Surgery.
Tuesday, July 16, 2013
Scientific News
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Promising Drug for Parkinson's Disease
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson’s disease, scientists from the University of Sheffield have discovered.
Benefits of Early Antiretroviral Therapy in HIV Infection
Scientists have explored the clinical importance of starting treatment early in individuals suffering with HIV.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!